WO2006114284A3 - AGONISTIC ANTIBODIES THAT BIND TO THE LT-β-RECEPTOR AND THEREBY MODULATE ADIPOSITY-ASSOCIATED PHENOTYPES AS WELL AS THEIR USE IN THERAPY - Google Patents

AGONISTIC ANTIBODIES THAT BIND TO THE LT-β-RECEPTOR AND THEREBY MODULATE ADIPOSITY-ASSOCIATED PHENOTYPES AS WELL AS THEIR USE IN THERAPY Download PDF

Info

Publication number
WO2006114284A3
WO2006114284A3 PCT/EP2006/003828 EP2006003828W WO2006114284A3 WO 2006114284 A3 WO2006114284 A3 WO 2006114284A3 EP 2006003828 W EP2006003828 W EP 2006003828W WO 2006114284 A3 WO2006114284 A3 WO 2006114284A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
adiposity
well
modulate
bind
Prior art date
Application number
PCT/EP2006/003828
Other languages
French (fr)
Other versions
WO2006114284A2 (en
Inventor
Dieter Link
Original Assignee
Pluta Rechtsanwalts Gmbh
Rechtsanwalt Dr Martin Prager
Dieter Link
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05009012A external-priority patent/EP1764371A1/en
Application filed by Pluta Rechtsanwalts Gmbh, Rechtsanwalt Dr Martin Prager, Dieter Link filed Critical Pluta Rechtsanwalts Gmbh
Publication of WO2006114284A2 publication Critical patent/WO2006114284A2/en
Publication of WO2006114284A3 publication Critical patent/WO2006114284A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to agonists of the LT-β-receptor as well as their use for activating the signal pathway of the lymphotoxin-β-receptor for interfering and/or modulating the differentiation of adipocytes and for use in adiposity/obesity and/or metabolic syndrome. In particular, the invention relates to agonists, preferably antibodies that inhibit the differentiation of pre-adipocytes to mature adipocytes and/or the storage of lipid molecules in differentiating or mature adipocytes by receptor-mediated signal transduction.
PCT/EP2006/003828 2005-04-25 2006-04-25 AGONISTIC ANTIBODIES THAT BIND TO THE LT-β-RECEPTOR AND THEREBY MODULATE ADIPOSITY-ASSOCIATED PHENOTYPES AS WELL AS THEIR USE IN THERAPY WO2006114284A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05009012A EP1764371A1 (en) 2005-04-25 2005-04-25 Agonist antibodies that bind to the LT-beta receptor, thereby modulating adiposity-associated phenotypes, and their use in therapy
EP05009012.5 2005-04-25
US68981405P 2005-06-13 2005-06-13
US60/689,814 2005-06-13

Publications (2)

Publication Number Publication Date
WO2006114284A2 WO2006114284A2 (en) 2006-11-02
WO2006114284A3 true WO2006114284A3 (en) 2006-12-28

Family

ID=36992645

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/003828 WO2006114284A2 (en) 2005-04-25 2006-04-25 AGONISTIC ANTIBODIES THAT BIND TO THE LT-β-RECEPTOR AND THEREBY MODULATE ADIPOSITY-ASSOCIATED PHENOTYPES AS WELL AS THEIR USE IN THERAPY

Country Status (1)

Country Link
WO (1) WO2006114284A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
JP2024508207A (en) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ LTBR agonists in combination therapy against cancer
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013808A2 (en) * 1992-12-04 1994-06-23 Biogen, Inc. LYMPHOTOXIN-β, LYMPHOTOXIN-β COMPLEXES, PHARMACEUTICAL PREPARATIONS AND THERAPEUTIC USES THEREOF
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US20020197254A1 (en) * 1996-10-25 2002-12-26 Browning Jeffrey L. Soluble lymphotoxin beta receptor and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013808A2 (en) * 1992-12-04 1994-06-23 Biogen, Inc. LYMPHOTOXIN-β, LYMPHOTOXIN-β COMPLEXES, PHARMACEUTICAL PREPARATIONS AND THERAPEUTIC USES THEREOF
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US20020197254A1 (en) * 1996-10-25 2002-12-26 Browning Jeffrey L. Soluble lymphotoxin beta receptor and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for treatment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CROWE P D ET AL: "A Lymphotoxin-Beta-Specific Receptor", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 264, no. 5159, 29 April 1994 (1994-04-29), pages 707 - 710, XP002003806, ISSN: 0036-8075 *
TILLER GABRIELE ET AL: "Effects of LIGHT (TNFSF14) on in vitro differentiation of human primary preadipocytes", INTERNATIONAL JOURNAL OF OBESITY, vol. 29, no. Suppl. 3, October 2005 (2005-10-01), & 4TH INTERNATIONAL SYMPOSIUM ON OBESITY AND HYPERTENSION; BERLIN, GERMANY; OCTOBER 27 -29, 2005, pages S5, XP009072849, ISSN: 0307-0565 *

Also Published As

Publication number Publication date
WO2006114284A2 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
WO2006125632A3 (en) Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy
WO2009099641A3 (en) Stabilized protein compositions
MX2009005935A (en) Chemical compounds and uses.
WO2008008887A3 (en) Gpr119 agonists for treating metabolic disorders
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
WO2007075439A3 (en) Compositions and methods for treating obesity and related metabolic disorders
WO2007090068A3 (en) Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif)
MX2012009088A (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor.
WO2008008286A3 (en) Substituted pyrazoles as ghrelin receptor antagonists
TW200833820A (en) Liquid-crystalline medium
WO2008119527A3 (en) Agonists of bitter taste receptors and uses thereof
WO2013070615A8 (en) Combination therapies using anti- pseudomonas psl and pcrv binding molecules
MX337454B (en) Aqueous composition comprising bromhexine.
WO2008063842A3 (en) Methods of treating neuropathic pain with agonists of ppar-gamma
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
WO2008150530A3 (en) Cripto binding molecules
WO2010048358A3 (en) Ethoxyphenylmethyl inhibitors of sglt2
WO2010081679A3 (en) Antibodies against human epo receptor
WO2008085221A3 (en) Therapeutic use of cd31 expressing cells
MX2011011768A (en) Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both.
MX359639B (en) METHODS and COMPOSITIONS FOR USE IN CELLULAR THERAPIES.
WO2008002449A3 (en) Glycomimetic inhibitors of siglec-8
WO2008136774A8 (en) Antibodies binding to an intracellular prl-1 or prl-3 polypeptide
WO2008010162A3 (en) Intracellular targeting of molecules
WO2008021250A3 (en) Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06724565

Country of ref document: EP

Kind code of ref document: A2